Winfield Associates’s CRISPR Therapeutics CRSP Stock Holding History

Winfield Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,700	Closed	-$205K	–	155
2021 Q4	$205K	Sell	2,700 -1,350	-33%	-$118K	0.07%	150
2021 Q3	$453K	Sell	4,050 -500	-11%	-$62.8K	0.17%	106
2021 Q2	$737K	Buy	4,550 +300	+7%	+$36.5K	0.27%	80
2021 Q1	$518K	Buy	4,250 +2,710	+176%	+$409K	0.21%	90
2020 Q4	$236K	Buy	+1,540	New	+$182K	0.1%	116

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Winfield Associates's CRSP Position: Q1 2022 in Review

Winfield Associates sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 2,700 shares — an estimated $205K sold.

Winfield Associates first reported a position in CRSP in Q4 2020 and held it in 5 quarters. The position peaked at $737K in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Winfield Associates reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Winfield Associates sold 2,700 CRISPR Therapeutics shares in Q1 2022, an estimated $205K.
Winfield Associates first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 5 quarters.
Winfield Associates's CRISPR Therapeutics position peaked at $737K in Q2 2021.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Winfield Associates's 13F filing for Q1 2022, filed 5 Apr 2022.